Skip to main content

LCD L34659: Endoscopic Treatment of GERD

LCD L34659, Endoscopic Treatment of GERD, is the Local Coverage Determination that Wisconsin Physicians Service Insurance Corporation applies to claims from 48 states (AK, AL, AR, AZ, CA, CO, CT, DE and others), effective 2026-07-30 and first in force 2015-10-01. The policy text runs 501 words, and its billing and coding article A56395 lists 3 ICD-10-CM codes that support medical necessity for 5 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wisconsin Physicians Service Insurance Corporation
States and territories
48
AK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY
Revision effective
2026-07-30
Original effective
2015-10-01
Policy text
501 words
Covered ICD-10 codes (articles)
3

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L34659
ContractContractorTypeStates
05101Wisconsin Physicians Service Insurance CorporationMAC - Part AIA
05201Wisconsin Physicians Service Insurance CorporationMAC - Part AKS
05301Wisconsin Physicians Service Insurance CorporationMAC - Part AMO
05401Wisconsin Physicians Service Insurance CorporationMAC - Part ANE
05102Wisconsin Physicians Service Insurance CorporationMAC - Part BIA
05202Wisconsin Physicians Service Insurance CorporationMAC - Part BKS
05302Wisconsin Physicians Service Insurance CorporationMAC - Part BMO
05402Wisconsin Physicians Service Insurance CorporationMAC - Part BNE
08101Wisconsin Physicians Service Insurance CorporationMAC - Part AIN
08102Wisconsin Physicians Service Insurance CorporationMAC - Part BIN
08201Wisconsin Physicians Service Insurance CorporationMAC - Part AMI
08202Wisconsin Physicians Service Insurance CorporationMAC - Part BMI
05901Wisconsin Physicians Service Insurance CorporationMAC - Part AAK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY

Billing and coding article A56395: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56395 (Billing and Coding: Endoscopic Treatment of GERD) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56395: Billing and Coding: Endoscopic Treatment of GERD (Billing and Coding, effective 2026-06-16)

Covered ICD-10-CM codes
3
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
5
Full article
cms.gov record
First 3 covered ICD-10-CM codes in A56395
ICD-10-CMDescription (FY2027)
K21.00Gastro-esophageal reflux disease with esophagitis, without bleeding
K21.01Gastro-esophageal reflux disease with esophagitis, with bleeding
K21.9Gastro-esophageal reflux disease without esophagitis

Procedure codes: 43210, 43257, 43499, 43999, 49999.

Coverage indications, limitations and medical necessity

Benefits are not available for endoluminal treatment for Gastroesophageal Reflux Disease (GERD) using the Stretta® procedure, the Bard EndoCinch™ Suturing System, Plicator™, or similar treatments as these procedures are not considered reasonable and necessary for the diagnosis or treatment of an injury or disease.

Currently, these procedures are considered non-covered due to the fact that current peer-reviewed literature does not support the efficacy of the services. Claims will be denied as "not proven effective."

The Stretta® procedure is an endoluminal treatment for GERD in which radiofrequency energy is delivered to smooth muscle of the lower esophageal sphincter (LES). A flexible catheter equipped with special needle electrodes for precise energy delivery is placed by mouth into the esophagus and carefully controlled radiofrequency energy is then delivered to the LES and gastric cardia, creating thermal lesions. The manufacturer maintains that the changes that occur immediately, and over time, result in a "tighter" LES and a less compliant gastric cardia. Additionally, the interruption of nerve pathways in the LES area is believed to reduce the incidence of inappropriate LES "relaxations," leading to an improvement in GERD symptoms. Substantial peer-reviewed evidence to fully support these assumptions remains to be published.

The Bard EndoCinch™ Suturing System and the Plicator™ are intended for use in endoscopic placement of suture(s) in the soft tissue of the esophagus and stomach and for approximation of tissue for treatment of symptomatic gastroesophageal reflux disease.

Clinical data from various studies are emerging. Currently, open-label studies or patient registries with short-term follow-ups are the dominant source of data. The overwhelming preponderance of reviewers remains equivocal in their support and have called for randomized controlled trials with long-term follow-ups. In the absence of evidence from such studies, and in the absence of wide acceptance, endoscopic treatments for GERD are not proven effective.

Therefore, they are not reimbursable even though some of the treatments may have associated CPT™ or OPPS codes.

Coverage for the TIF (Transoral Incisionless Fundoplication) procedure is for treatment of patients in whom proton pump inhibitor therapy fails. An example of the device used in TIF is EsophyX™. TIF using EsophyX™ for performing surgery for treating gastroesophageal reflux disease (GERD) reconstructs the valve at the top of the stomach that helps prevents acid reflux.

Indications

Coverage is appropriate for TIF if done by a well-trained surgeon for the following indications:

1. Symptomatic chronic gastroesophageal reflux (chronic being defined as > 6 months of symptoms), and

2. Symptoms must not be completely responsive to Proton Pump Inhibitors (PPIs) as judged by GERD HRQL scores of or equal to 20 when off for 14 days (also acceptable would be the difference of > or equal to 10 of the scores between off and on therapy), and

3. Hiatal hernia TIF procedure. (Based on (FDA) approval).

Limitations

Coverage is not extended:

1. For those patients who may have recurrent symptoms or may fail this procedure. No literature has been submitted for repeat TIF use. These procedures (repeat TIF) would be considered investigational at this time.

Summary of evidence (opening)

Summary of evidence for TIF: June 2020

• Chang CG, Thackeray L. Laparoscopic Hiatal Hernia Repair in 221 Patients: Outcomes and Experience. JSLS . 2016;20(1):e2015.00104. doi:10.4293/JSLS.2015.00104. The article addresses the common condition of hiatal hernia, which is often associated with symptomatic gastroesophageal reflux disease (GERD). The article supported the studies outcomes of the efficacy and safety of laparoscopic hiatal hernia repair (LHHR) with biologic mesh to reduce and/or alleviate GERD symptoms and associated hiatal hernia recurrence. The greatest GERD-HRQL score decrease (20.5 ± 13.4) was observed in patients who underwent LHHR with a fundoplication procedure (Nissen/TIF).

• Ihde GM, Besancon K, Deljkich E. Short-term safety and symptomatic outcomes of transoral incisionless fundoplication with or without hiatal hernia repair in patients with chronic gastroesophageal reflux disease. Am J Surg . 2011; 202(6):740-747. doi:10.1016/j.amjsurg.2011.06.035. The study supports the safety of TIF and the procedure’s ability to significantly reduce the symptoms. The technology represents a suitable alternative treatment option to patients with chronic GERD not satisfied with their current management of the disease. The use of laparoscopic HHR can augment the use of transoral fundoplication without introducing the side effects of laparoscopic Nissen fundoplication (LNF).

• Ihde GM 2nd, Pena C, Scitern C, Brewer S. pH Scores in Hiatal Repair with Transoral Incisionless Fundoplication. JSLS . 2019;23(1):e2018.00087. doi:10.4293/JSLS.2018.00087. This article supports that hiatal hernia repair combined with transoral incisionless fundoplication significantly improved outcomes in patients with gastroesophageal reflux disease in both subjective Gastroesophageal Reflux Disease Health Related Quality of Life and Reflux Symptom Index measurements as well as in objective pH scores.

The contractor cites 16 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2026-07-30
Last reviewed by the contractor
2026-06-25
MCD version
32
Derived from
L30473

The contractor lists 2 National Coverage Determinations as related: NCD 100.2 Endoscopy, NCD 100.3 24-Hour Ambulatory Esophageal pH Monitoring. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A58568 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wisconsin Physicians Service Insurance Corporation hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L34659 cover?

Benefits are not available for endoluminal treatment for Gastroesophageal Reflux Disease (GERD) using the Stretta® procedure, the Bard EndoCinch™ Suturing System, Plicator™, or similar treatments as these procedures are not considered reasonable and necessary for the diagnosis or treatment of an injury or disease. The full 501-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L34659 apply to?

Wisconsin Physicians Service Insurance Corporation applies it to Medicare claims in 48 states: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L34659?

The companion billing and coding article A56395 lists 3 ICD-10-CM codes in 1 group that support medical necessity; the first 3 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L34659?

A denial under LCD L34659 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56395's 3 covered diagnosis codes, then file a redetermination with Wisconsin Physicians Service Insurance Corporation within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.